Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
NewsA promising new eye drug is making waves in retinal disease treatment. OLN324, a dual VEGF and Ang-2 inhibitor, matched faricimab in improving retinal fluid and anatomy in wet AMD and diabetic macular edema — and dried the retina faster and more effectively in both conditions. Phase 3 trials are on the horizon.
OLN324 (Ollin Biosciences), a novel dual VEGF and Ang-2 inhibitor, is generating significant interest in the ophthalmology community. Results from the JADE proof-of-concept trial — presented at Clinical Trials at the Summit — show that OLN324 achieved retinal fluid and anatomic improvements comparable to faricimab (Vabysmo, Genentech) in patients with wet age-related macular degeneration (AMD), while also demonstrating faster and greater reductions in pigment epithelial detachment thickness that were sustained longer than faricimab.
In patients with diabetic macular edema (DME), OLN324 also outperformed faricimab on speed of drying from week 1 all the way through week 20. Vision gains were seen across all treatment arms, and the drug's safety profile was clean — no cases of intraocular inflammation were reported in either OLN324 group.
Why it matters: OLN324 is being described as the only treatment to demonstrate superior anatomic efficacy over faricimab in a randomized controlled study — a notable finding in a competitive space. With Phase 3 trials expected to launch later this year, this drug could reshape treatment standards for two of the most common causes of vision loss.
